mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2025-1-83-90mrj-1707Research ArticleОБЗОРЫREVIEWSИзвестные лабораторные нарушения и потенциальные молекулы-мишени для консервативного лечения аваскулярного остеонекрозаKnown laboratory abnormalities and potential targets for the conservative treatment of avascular osteonecrosishttps://orcid.org/0000-0002-3745-0924БяликВ. Е.BialikV. E.

Валерий Евгеньевич Бялик,

115522, Москва, Каширское шоссе, 34А

Valery Evgenievich Bialik,

34A, Kashirskoe Shosse, Moscow 115522

DoctorBjalik@yandex.ruhttps://orcid.org/0000-0002-5626-7404МакаровМ. А.MakarovM. A.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0001-7938-1536БяликЕ. И.BialikE. I.

115522, Москва, Каширское шоссе, 34А;

125993, Москва, ул. Баррикадная, 2/1, стр. 1

34A, Kashirskoe Shosse, Moscow 115522;

2/1, Barrikadnaya Street, Build. 1, Moscow 125993

https://orcid.org/0000-0001-8563-0631МакаровС. А.MakarovS. A.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0002-1391-0711КаратеевА. Е.KarateevA. E.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

115522, Москва, Каширское шоссе, 34А;

125993, Москва, ул. Баррикадная, 2/1, стр. 1

34A, Kashirskoe Shosse, Moscow 115522;

2/1, Barrikadnaya Street, Build. 1, Moscow 125993

https://orcid.org/0000-0002-7179-8174НестеренкоВ. А.NesterenkoV. A.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0002-5256-7346БяликА. А.BialikA. A.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0002-0454-0974КапитоновД. В.KapitonovD. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0009-0009-5068-3536ГореловаА. И.GorelovaA. I.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Federation2025150220251918390Copyright © Бялик В.Е., Макаров М.А., Бялик Е.И., Макаров С.А., Каратеев А.Е., Лила А.М., Нестеренко В.А., Бялик А.А., Капитонов Д.В., Горелова А.И., 20252025Бялик В.Е., Макаров М.А., Бялик Е.И., Макаров С.А., Каратеев А.Е., Лила А.М., Нестеренко В.А., Бялик А.А., Капитонов Д.В., Горелова А.И.Bialik V.E., Makarov M.A., Bialik E.I., Makarov S.A., Karateev A.E., Lila A.M., Nesterenko V.A., Bialik A.A., Kapitonov D.V., Gorelova A.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1707

Аваскулярный остеонекроз (АОН) – распространенная патология, которая наиболее часто поражает людей трудоспособного возраста (20–60 лет). Заболевание приводит к быстрому разрушению и коллапсу субхондральной кости с последующим развитием вторичного остеоартрита пораженного сустава.

Представлен обзор современных данных о лабораторных нарушениях при АОН. Подробно описаны биомаркеры, имеющие прямую связь с развитием и прогрессированием АОН. Сформулированы идеи для будущих исследований, которые помогут улучшить выявление и лечения заболевания.

Avascular osteonecrosis (AON) is a common condition that most often affects people of working age (20–60 years). The disease leads to rapid destruction and collapse of the subchondral bone with subsequent development of secondary osteoarthritis of the affected joint. The current data on laboratory abnormalities in AON are presented. Biomarkers directly related to the development and progression of AON are described in detail. Ideas for future research are formulated to improve the detection and treatment of the disease.

аваскулярный остеонекрозтромбофилиягипофибринолизRANKLостеопротегеринадипонектинамилоид Аα2-макроглобулинavascular osteonecrosisthrombophiliahypofibrinolysisRANKLosteoprotegerinadiponectinamyloid Aα2-macroglobulinReferencesBergman J, Nordstrцm A, Nordstrцm P. Epidemiology of osteonecrosis among older adults in Sweden. Osteoporos Int. 2019 May; 30(5):965-973. doi: 10.1007/s00198-018-04826-2. Epub 2019 Jan 9.Bergman J, Nordstrцm A, Nordstrцm P. Epidemiology of osteonecrosis among older adults in Sweden. Osteoporos Int. 2019 May; 30(5):965-973. doi: 10.1007/s00198-018-04826-2. Epub 2019 Jan 9.Мустафин РН. Аваскулярный некроз головки бедренной кости в Республике Башкортостан (клинико-эпидемиологическое исследование). Креативная хирургия и онкология. 2020;10(2):100-107.Mustafin RN. Avascular Necrosis of Femoral Head in the Republic of Bashkortostan: a Clinical and Epidemiological Study. Kreativnaya khirurgiya i onkologiya. 2020;10(2):100-107 (In Russ.).Chang C, Greenspan A, Gershwin ME. The pathogenesis, diagnosis and clinical manifestations of steroid-induced osteonecrosis. J Autoimmun. 2020 Jun:110:102460. doi: 10.1016/j.jaut.2020.102460. Epub 2020 Apr 16.Chang C, Greenspan A, Gershwin ME. The pathogenesis, diagnosis and clinical manifestations of steroid-induced osteonecrosis. J Autoimmun. 2020 Jun:110:102460. doi: 10.1016/j.jaut.2020.102460. Epub 2020 Apr 16.Тихилов РМ, Шубняков ИИ, редакторы. Руководство по хирургии тазобедренного сустава. Том 1. Санкт-Петербург: РНИИТО им. Р. Р. Вредена; 2014. 368 с.Tikhilov RM, Shubnyakov II, editors. Guidelines for hip joint surgery. Volume 1. Saint Petersburg: RNIITO im. R. R. Vredena; 2014. 368 p.Lespasio MJ, Sodhi N, Mont MA. Osteonecrosis of the Hip: A Primer. Perm J. 2019:23:18-100. doi: 10.7812/TPP/18-100.Lespasio MJ, Sodhi N, Mont MA. Osteonecrosis of the Hip: A Primer. Perm J. 2019:23:18-100. doi: 10.7812/TPP/18-100.Glueck CJ, Freiberg R, Tracy T, et al. Thrombophilia and hypofibrinolysis: Pathophysiologies of osteonecrosis. Clin Orthop Relat Res. 1997 Jan:(334):43-56.Glueck CJ, Freiberg R, Tracy T, et al. Thrombophilia and hypofibrinolysis: Pathophysiologies of osteonecrosis. Clin Orthop Relat Res. 1997 Jan:(334):43-56.Kubo T, Tsuji H, Yamamoto T, et al. Antithrombin III deficiency in a patient with multifocal osteonecrosis. Clin Orthop Relat Res. 2000 Sep:(378):306-11. doi: 10.1097/00003086-200009000-00041.Kubo T, Tsuji H, Yamamoto T, et al. Antithrombin III deficiency in a patient with multifocal osteonecrosis. Clin Orthop Relat Res. 2000 Sep:(378):306-11. doi: 10.1097/00003086-200009000-00041.Pierre-Jacques H, Glueck CJ, Mont MA, Hungerford DS. Familial heterozygous protein-S deficiency in a patient who had multifocal osteonecrosis. A case report. J Bone Joint Surg Am. 1997 Jul;79(7):1079-84. doi: 10.2106/00004623-199707000-00017.Pierre-Jacques H, Glueck CJ, Mont MA, Hungerford DS. Familial heterozygous protein-S deficiency in a patient who had multifocal osteonecrosis. A case report. J Bone Joint Surg Am. 1997 Jul;79(7):1079-84. doi: 10.2106/00004623-199707000-00017.Glueck CJ, Freiberg RA, Fontaine RN, et al. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res. 2001 May:(386):19-33. doi: 10.1097/00003086- 200105000-00004.Glueck CJ, Freiberg RA, Fontaine RN, et al. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res. 2001 May:(386):19-33. doi: 10.1097/00003086- 200105000-00004.Zalavras CG, Vartholomatos G, Dokou E, Malizos KN. Factor V Leiden and prothrombin gene mutations in femoral head osteonecrosis. Thromb Haemost. 2002 Jun;87(6): 1079-80.Zalavras CG, Vartholomatos G, Dokou E, Malizos KN. Factor V Leiden and prothrombin gene mutations in femoral head osteonecrosis. Thromb Haemost. 2002 Jun;87(6): 1079-80.Garcia FL, Ramalli Junior EL, Picado CHF. Coagulation disorders in patients with femoral head osteonecrosis. Acta Ortop Bras. 2013 Jan;21(1):43-5. doi: 10.1590/S1413-78522013000100009.Garcia FL, Ramalli Junior EL, Picado CHF. Coagulation disorders in patients with femoral head osteonecrosis. Acta Ortop Bras. 2013 Jan;21(1):43-5. doi: 10.1590/S1413-78522013000100009.Arruda VR, Belangero WD, Ozelo MC, et al. Inherited risk factors for thrombophilia among children with Legg-Calve-Perthes disease. J Pediatr Orthop. 1999 Jan-Feb;19(1):84-7.Arruda VR, Belangero WD, Ozelo MC, et al. Inherited risk factors for thrombophilia among children with Legg-Calve-Perthes disease. J Pediatr Orthop. 1999 Jan-Feb;19(1):84-7.Bjorkman A, Burtscher IM, Svensson PJ, et al. Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee. Arch Orthop Trauma Surg. 2005 Feb;125(1):51-5. doi: 10.1007/s00402-004-0760-8. Epub 2004 Nov 18.Bjorkman A, Burtscher IM, Svensson PJ, et al. Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee. Arch Orthop Trauma Surg. 2005 Feb;125(1):51-5. doi: 10.1007/s00402-004-0760-8. Epub 2004 Nov 18.Baek SH, Kim KH, Lee WK, et al. Abnormal Lipid Profiles in Nontraumatic Osteonecrosis of the Femoral Head: A Comparison with Osteoarthritis Using Propensity Score Matching. J Bone Joint Surg Am. 2022 Apr 6;104(Suppl 2):19-24. doi: 10.2106/JBJS.20.00520.Baek SH, Kim KH, Lee WK, et al. Abnormal Lipid Profiles in Nontraumatic Osteonecrosis of the Femoral Head: A Comparison with Osteoarthritis Using Propensity Score Matching. J Bone Joint Surg Am. 2022 Apr 6;104(Suppl 2):19-24. doi: 10.2106/JBJS.20.00520.Glueck C, Fontaine R, Gruppo R, et al. The Plasminogen Activator Inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop Relat Res. 1999 Sep:(366):133-46. doi: 10.1097/00003086-199909000-00017.Glueck C, Fontaine R, Gruppo R, et al. The Plasminogen Activator Inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop Relat Res. 1999 Sep:(366):133-46. doi: 10.1097/00003086-199909000-00017.Glueck C, Freiberg R, Wang P. Heritable thrombophilia-hypofibrinolysis and osteonecrosis of the femoral head. Clin Orthop Relat Res. 2008 May;466(5):1034-40. doi: 10.1007/s11999-008-0148-0. Epub 2008 Mar 19.Glueck C, Freiberg R, Wang P. Heritable thrombophilia-hypofibrinolysis and osteonecrosis of the femoral head. Clin Orthop Relat Res. 2008 May;466(5):1034-40. doi: 10.1007/s11999-008-0148-0. Epub 2008 Mar 19.Chotanaphuti T, Heebthamai D, Chuwong M, Kanchanaroek K. The prevalence of thrombophilia in idiopathic osteonecrosis of the hip. J Med Assoc Thai. 2009 Dec;92 Suppl 6:S141-6.Chotanaphuti T, Heebthamai D, Chuwong M, Kanchanaroek K. The prevalence of thrombophilia in idiopathic osteonecrosis of the hip. J Med Assoc Thai. 2009 Dec;92 Suppl 6:S141-6.Glueck CJ, Glueck HI, Mieczkowski L, et al. Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis? Thromb Haemost. 1993 May 3;69(5):460-5.Glueck CJ, Glueck HI, Mieczkowski L, et al. Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis? Thromb Haemost. 1993 May 3;69(5):460-5.Asherson RA, Liote F, Page B, et al. Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol. 1993 Feb;20(2):284-8.Asherson RA, Liote F, Page B, et al. Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol. 1993 Feb;20(2):284-8.Korompilias AV, Gilkeson GS, Ortel TL, et al. Anticardiolipin antibodies and osteonecrosis of the femoral head. Clin Orthop Relat Res. 1997 Dec:(345):174-80.Korompilias AV, Gilkeson GS, Ortel TL, et al. Anticardiolipin antibodies and osteonecrosis of the femoral head. Clin Orthop Relat Res. 1997 Dec:(345):174-80.Hirata T, Fujioka M, Takahashi KA, et al. Low molecular weight phenotype of Apo(a) is a risk factor of corticosteroid-induced osteonecrosis of the femoral head after renal transplant. J Rheumatol. 2007 Mar;34(3):516-22.Hirata T, Fujioka M, Takahashi KA, et al. Low molecular weight phenotype of Apo(a) is a risk factor of corticosteroid-induced osteonecrosis of the femoral head after renal transplant. J Rheumatol. 2007 Mar;34(3):516-22.Hussein S, Suitner M, Beland-Bonenfant S, et al. Monitoring of osteonecrosis in systemic lupus erythematosus: A systematic review and metaanalysis. J Rheumatol. 2018 Oct;45(10): 1462-1476. doi: 10.3899/jrheum.170837. Epub 2018 Jul 1.Hussein S, Suitner M, Beland-Bonenfant S, et al. Monitoring of osteonecrosis in systemic lupus erythematosus: A systematic review and metaanalysis. J Rheumatol. 2018 Oct;45(10): 1462-1476. doi: 10.3899/jrheum.170837. Epub 2018 Jul 1.Haydock MM, Elhamdani S, Alsharedi M. Long-term direct oral anticoagulation in primary osteonecrosis with elevated plasminogen activation inhibitor. SAGE Open Med Case Rep. 2019 Feb 4:7:2050313X19827747. doi: 10.1177/2050313X19827747. eCollection 2019.Haydock MM, Elhamdani S, Alsharedi M. Long-term direct oral anticoagulation in primary osteonecrosis with elevated plasminogen activation inhibitor. SAGE Open Med Case Rep. 2019 Feb 4:7:2050313X19827747. doi: 10.1177/2050313X19827747. eCollection 2019.Jarman MI, Lee K, Kanevsky A, et al. Case report: primary osteonecrosis associated with thrombophilia-hypofibrinolysis and worsened by testosterone therapy. BMC Hematol. 2017 Mar 27:17:5. doi: 10.1186/s12878-017-0076-x. eCollection 2017.Jarman MI, Lee K, Kanevsky A, et al. Case report: primary osteonecrosis associated with thrombophilia-hypofibrinolysis and worsened by testosterone therapy. BMC Hematol. 2017 Mar 27:17:5. doi: 10.1186/s12878-017-0076-x. eCollection 2017.Fu W, Liu B, Wang B, Zhao D. Early diagnosis and treatment of steroid-induced osteonecrosis of the femoral head. Int Orthop. 2019 May;43(5):1083-1087. doi: 10.1007/s00264-018-4011-y. Epub 2018 Jun 6.Fu W, Liu B, Wang B, Zhao D. Early diagnosis and treatment of steroid-induced osteonecrosis of the femoral head. Int Orthop. 2019 May;43(5):1083-1087. doi: 10.1007/s00264-018-4011-y. Epub 2018 Jun 6.Glueck CJ, Freiberg RA, Wissman R, Wang P. Long term anticoagulation (4-16 years) stops progression of idiopathic hip osteonecrosis associated with familial thrombophilia. Adv Orthop. 2015:2015:138382. doi: 10.1155/2015/138382. Epub 2015 Jan 29.Glueck CJ, Freiberg RA, Wissman R, Wang P. Long term anticoagulation (4-16 years) stops progression of idiopathic hip osteonecrosis associated with familial thrombophilia. Adv Orthop. 2015:2015:138382. doi: 10.1155/2015/138382. Epub 2015 Jan 29.Guo P, Gao F, Wang Y, et al. The use of anticoagulants for prevention and treatment of osteonecrosis of the femoral head: A systematic review. Medicine (Baltimore). 2017 Apr; 96(16):e6646. doi: 10.1097/MD.0000000000006646.Guo P, Gao F, Wang Y, et al. The use of anticoagulants for prevention and treatment of osteonecrosis of the femoral head: A systematic review. Medicine (Baltimore). 2017 Apr; 96(16):e6646. doi: 10.1097/MD.0000000000006646.Yu X, Zhang S, Zhang B, Dai M. Relationship of idiopathic femoral head necrosis with blood lipid metabolism and coagulation function: A propensity score-based analysis. Front Surg. 2023 Jan 6:9:938565. doi: 10.3389/fsurg.2022.938565. eCollection 2022.Yu X, Zhang S, Zhang B, Dai M. Relationship of idiopathic femoral head necrosis with blood lipid metabolism and coagulation function: A propensity score-based analysis. Front Surg. 2023 Jan 6:9:938565. doi: 10.3389/fsurg.2022.938565. eCollection 2022.Zeng X, Zhan K, Zhang L, et al. The impact of high total cholesterol and high lowdensity lipoprotein on avascular necrosis of the femoral head in low-energy femoral neck fractures. J Orthop Surg Res. 2017 Feb 17; 12(1):30. doi: 10.1186/s13018-017-0532-0.Zeng X, Zhan K, Zhang L, et al. The impact of high total cholesterol and high lowdensity lipoprotein on avascular necrosis of the femoral head in low-energy femoral neck fractures. J Orthop Surg Res. 2017 Feb 17; 12(1):30. doi: 10.1186/s13018-017-0532-0.Mogensen SS, Schmiegelow K, Grell K, et al. Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia. Haematologica. 2017 May;102(5):e175-e178. doi: 10.3324/haematol.2016.160507. Epub 2017 Feb 16.Mogensen SS, Schmiegelow K, Grell K, et al. Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia. Haematologica. 2017 May;102(5):e175-e178. doi: 10.3324/haematol.2016.160507. Epub 2017 Feb 16.Nishida K, Yamamoto T, Motomura G, et al. Pitavastatin may reduce risk of steroidinduced osteonecrosis in rabbits: a preliminary histological study. Clin Orthop Relat Res. 2008 May;466(5):1054-8. doi: 10.1007/s11999-008-0189-4. Epub 2008 Mar 19.Nishida K, Yamamoto T, Motomura G, et al. Pitavastatin may reduce risk of steroidinduced osteonecrosis in rabbits: a preliminary histological study. Clin Orthop Relat Res. 2008 May;466(5):1054-8. doi: 10.1007/s11999-008-0189-4. Epub 2008 Mar 19.Yang Z, Liu H, Li D, et al. The efficacy of statins in preventing glucocorticoid-related osteonecrosis in animal models: A metaanalysis. Bone Joint Res. 2016 Sep;5(9):393- 402. doi: 10.1302/2046-3758.59.2000500.Yang Z, Liu H, Li D, et al. The efficacy of statins in preventing glucocorticoid-related osteonecrosis in animal models: A metaanalysis. Bone Joint Res. 2016 Sep;5(9):393- 402. doi: 10.1302/2046-3758.59.2000500.Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Relat Res. 2001 May: (386):173-8. doi: 10.1097/00003086-200105000-00022.Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Relat Res. 2001 May: (386):173-8. doi: 10.1097/00003086-200105000-00022.Mont MA, Pivec R, Banerjee S, et al. High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review. J Arthroplasty. 2015 Sep;30(9):1506-1512.e5. doi: 10.1016/j.arth.2015.03.036. Epub 2015 Apr 8.Mont MA, Pivec R, Banerjee S, et al. High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review. J Arthroplasty. 2015 Sep;30(9):1506-1512.e5. doi: 10.1016/j.arth.2015.03.036. Epub 2015 Apr 8.Yin H, Yuan Z, Wang D. Multiple drilling combined with simvastatin versus multiple drilling alone for the treatment of avascular osteonecrosis of the femoral head: 3-year follow-up study. BMC Musculoskelet Disord. 2016 Aug 15;17(1):344. doi: 10.1186/s12891-016-1199-0.Yin H, Yuan Z, Wang D. Multiple drilling combined with simvastatin versus multiple drilling alone for the treatment of avascular osteonecrosis of the femoral head: 3-year follow-up study. BMC Musculoskelet Disord. 2016 Aug 15;17(1):344. doi: 10.1186/s12891-016-1199-0.Ajmal M, Matas AJ, Kuskowski M, Cheng EY. Does statin usage reduce the risk of corticosteroid-related osteonecrosis in renal transplant population? Orthop Clin North Am. 2009 Apr;40(2):235-9. doi: 10.1016/j.ocl.2009.01.004.Ajmal M, Matas AJ, Kuskowski M, Cheng EY. Does statin usage reduce the risk of corticosteroid-related osteonecrosis in renal transplant population? Orthop Clin North Am. 2009 Apr;40(2):235-9. doi: 10.1016/j.ocl.2009.01.004.Funck-Brentano T, Biver E, Chopin F, et al. Clinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring: a systematic review. Semin Arthritis Rheum. 2011 Oct;41(2):157-69. doi: 10.1016/j.semarthrit.2011.01.005. Epub 2011 Apr 19.Funck-Brentano T, Biver E, Chopin F, et al. Clinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring: a systematic review. Semin Arthritis Rheum. 2011 Oct;41(2):157-69. doi: 10.1016/j.semarthrit.2011.01.005. Epub 2011 Apr 19.Bhattoa HP, Cavalier E, Eastell R, et al. Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood. Clin Chim Acta. 2021 Apr:515:16-20. doi: 10.1016/j.cca.2020.12.023. Epub 2020 Dec 28.Bhattoa HP, Cavalier E, Eastell R, et al. Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood. Clin Chim Acta. 2021 Apr:515:16-20. doi: 10.1016/j.cca.2020.12.023. Epub 2020 Dec 28.Cavalier E, Eastell R, Jørgensen NR, et al. A Multicenter Study to Evaluate Harmonization of Assays for C-Terminal Telopeptides of Type I Collagen (β-CTX): A Report from the IFCC-IOF Committee for Bone Metabolism (C-BM). Calcif Tissue Int. 2021 Jun;108(6): 785-797. doi: 10.1007/s00223-021-00816-5. Epub 2021 Mar 4.Cavalier E, Eastell R, Jørgensen NR, et al. A Multicenter Study to Evaluate Harmonization of Assays for C-Terminal Telopeptides of Type I Collagen (β-CTX): A Report from the IFCC-IOF Committee for Bone Metabolism (C-BM). Calcif Tissue Int. 2021 Jun;108(6): 785-797. doi: 10.1007/s00223-021-00816-5. Epub 2021 Mar 4.Chubb SAP, Vasikaran SD. Measurement and Clinical Utility of β-CTX in Serum and Plasma. Adv Clin Chem. 2017:81:97-134. doi: 10.1016/bs.acc.2017.01.003. Epub 2017 Feb 16.Chubb SAP, Vasikaran SD. Measurement and Clinical Utility of β-CTX in Serum and Plasma. Adv Clin Chem. 2017:81:97-134. doi: 10.1016/bs.acc.2017.01.003. Epub 2017 Feb 16.Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol. 2014 Oct 20:5:511. doi: 10.3389/fimmu.2014.00511. eCollection 2014.Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol. 2014 Oct 20:5:511. doi: 10.3389/fimmu.2014.00511. eCollection 2014.Аганов ДС, Тыренко ВВ, Цыган ЕН и др. Роль цитокиновой системы RANKL/RANK/OPG в регуляции минерального обмена костной ткани. Гены & Клетки. 2014; XI(4):50-52.Aganov DS, Tyrenko VV, Tsygan EN, Toporkov MM, Bologov SG. The role of cytokine system RANKL/RANK/OPG in the regulation of bone metabolism. Geny & Kletki. 2014;XI(4):50-52. (In Russ.).Xiong MY, Liu LQ, Liu SQ, et al. Effects of osteoprotegerin, RANK and RANKL on bone destruction and collapse in avascular necrosis femoral head. Am J Transl Res. 2016 Jul 15;8(7):3133-40. eCollection 2016.Xiong MY, Liu LQ, Liu SQ, et al. Effects of osteoprotegerin, RANK and RANKL on bone destruction and collapse in avascular necrosis femoral head. Am J Transl Res. 2016 Jul 15;8(7):3133-40. eCollection 2016.Kovacs B, Vajda E, Nagy EE. Regulatory Effects and Interactions of the Wnt and OPGRANKL-RANK Signaling at the Bone-Cartilage Interface in Osteoarthritis. Int J Mol Sci. 2019 Sep 19;20(18):4653. doi: 10.3390/ijms20184653.Kovacs B, Vajda E, Nagy EE. Regulatory Effects and Interactions of the Wnt and OPGRANKL-RANK Signaling at the Bone-Cartilage Interface in Osteoarthritis. Int J Mol Sci. 2019 Sep 19;20(18):4653. doi: 10.3390/ijms20184653.He MC, Zhang J, Chen XJ, et al. Osteoclastic activity was associated with the development of steroid-induced osteonecrosis of femoral head. Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):1036-1046. doi: 10.1080/21691401.2020.1774596.He MC, Zhang J, Chen XJ, et al. Osteoclastic activity was associated with the development of steroid-induced osteonecrosis of femoral head. Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):1036-1046. doi: 10.1080/21691401.2020.1774596.Yue YB, Liu X, Wei BF. Attenuated serum adiponectin levels are associated with disease severity in patients with non-traumatic osteonecrosis of the femoral head. J Pain Res. 2017 Oct 3:10:2387-2393. doi: 10.2147/JPR. S143036. eCollection 2017.Yue YB, Liu X, Wei BF. Attenuated serum adiponectin levels are associated with disease severity in patients with non-traumatic osteonecrosis of the femoral head. J Pain Res. 2017 Oct 3:10:2387-2393. doi: 10.2147/JPR. S143036. eCollection 2017.Peng X, Ma Y, Wang Q, et al. Serum Amyloid A Correlates With the Osteonecrosis of Femoral Head by Affecting Bone Metabolism. Front Pharmacol. 2021 Oct 18:12:767243. doi: 10.3389/fphar.2021.767243. eCollection 2021.Peng X, Ma Y, Wang Q, et al. Serum Amyloid A Correlates With the Osteonecrosis of Femoral Head by Affecting Bone Metabolism. Front Pharmacol. 2021 Oct 18:12:767243. doi: 10.3389/fphar.2021.767243. eCollection 2021.Ghale-Noie ZN, Hassani M, Kachooei AR, Kerachian MA. High Serum Alpha-2-Macroglobulin Level in Patients with Osteonecrosis of the Femoral Head. Arch Bone Jt Surg. 2018 May;6(3):219-224.Ghale-Noie ZN, Hassani M, Kachooei AR, Kerachian MA. High Serum Alpha-2-Macroglobulin Level in Patients with Osteonecrosis of the Femoral Head. Arch Bone Jt Surg. 2018 May;6(3):219-224.Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone. 2004 Oct;35(4):842-9. doi: 10.1016/j.bone.2004.06.008.Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone. 2004 Oct;35(4):842-9. doi: 10.1016/j.bone.2004.06.008.Lenchik L, Register TC, Hsu FC, et al. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone. 2003 Oct;33(4):646-51. doi: 10.1016/s8756-3282(03)00237-0.Lenchik L, Register TC, Hsu FC, et al. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone. 2003 Oct;33(4):646-51. doi: 10.1016/s8756-3282(03)00237-0.Shuai B, Shen L, Yang YP, et al. Low plasma adiponectin as a potential biomarker for osteonecrosis of the femoral head. J Rheumatol. 2010 Oct;37(10):2151-5. doi: 10.3899/jrheum.100342. Epub 2010 Aug 3.Shuai B, Shen L, Yang YP, et al. Low plasma adiponectin as a potential biomarker for osteonecrosis of the femoral head. J Rheumatol. 2010 Oct;37(10):2151-5. doi: 10.3899/jrheum.100342. Epub 2010 Aug 3.Lloyd-Price J, Arze C, Ananthakrishnan AN, et al. Multi-omics of the Gut Microbial Ecosystem in Inflammatory Bowel Diseases. Nature. 2019 May;569(7758):655-662. doi: 10.1038/s41586-019-1237-9. Epub 2019 May 29.Lloyd-Price J, Arze C, Ananthakrishnan AN, et al. Multi-omics of the Gut Microbial Ecosystem in Inflammatory Bowel Diseases. Nature. 2019 May;569(7758):655-662. doi: 10.1038/s41586-019-1237-9. Epub 2019 May 29.Husebekk A, Skogen B, Husby G, Marhaug G. Transformation of Amyloid Precursor SAA to Protein AA and Incorporation in Amyloid Fibrils In Vivo. Scand J Immunol. 1985 Mar;21(3):283-7. doi: 10.1111/j.1365-3083.1985.tb01431.x.Husebekk A, Skogen B, Husby G, Marhaug G. Transformation of Amyloid Precursor SAA to Protein AA and Incorporation in Amyloid Fibrils In Vivo. Scand J Immunol. 1985 Mar;21(3):283-7. doi: 10.1111/j.1365-3083.1985.tb01431.x.Sack GH Jr. Serum amyloid A – a review. Mol Med. 2018 Aug 30;24(1):46. doi: 10.1186/s10020-018-0047-0.Sack GH Jr. Serum amyloid A – a review. Mol Med. 2018 Aug 30;24(1):46. doi: 10.1186/s10020-018-0047-0.Vandooren J, Itoh Y. Alpha-2-Macroglobulin in Inflammation, Immunity and Infections. Front Immunol. 2021 Dec 14:12:803244. doi: 10.3389/fimmu.2021.803244. eCollection 2021.Vandooren J, Itoh Y. Alpha-2-Macroglobulin in Inflammation, Immunity and Infections. Front Immunol. 2021 Dec 14:12:803244. doi: 10.3389/fimmu.2021.803244. eCollection 2021.Ekerot L, Ohlsson K. Immunoreactive Alpha 2-Macroglobulin in Rheumatoid Synovial Membrane. Scand J Plast Reconstr Surg. 1982;16(3):293-4. doi: 10.3109/02844318209026222.Ekerot L, Ohlsson K. Immunoreactive Alpha 2-Macroglobulin in Rheumatoid Synovial Membrane. Scand J Plast Reconstr Surg. 1982;16(3):293-4. doi: 10.3109/02844318209026222.Flory ED, Clarris BJ, Muirden KD. Deposits of Alpha 2M in the Rheumatoid Synovial Membrane. Ann Rheum Dis. 1982 Oct;41(5):520-6. doi: 10.1136/ard.41.5.520.Flory ED, Clarris BJ, Muirden KD. Deposits of Alpha 2M in the Rheumatoid Synovial Membrane. Ann Rheum Dis. 1982 Oct;41(5):520-6. doi: 10.1136/ard.41.5.520.

The authors declare that there are no conflicts of interest present.